MeiraGTx (MGTX) Projected to Post Earnings on Wednesday

MeiraGTx (NASDAQ:MGTX) is projected to release its Q3 2025 results before the market opens on Wednesday, November 12th. Analysts expect MeiraGTx to post earnings of ($0.51) per share and revenue of $7.7050 million for the quarter. Interested persons may visit the the company’s upcoming Q3 2025 earningresults page for the latest details on the call scheduled for Friday, November 14, 2025 at 12:30 PM ET.

MeiraGTx (NASDAQ:MGTX) last posted its earnings results on Thursday, August 14th. The company reported ($0.48) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.04. MeiraGTx had a negative net margin of 415.39% and a negative return on equity of 314.44%. The firm had revenue of $3.69 million during the quarter, compared to analyst estimates of $8.00 million. On average, analysts expect MeiraGTx to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

MeiraGTx Stock Performance

Shares of NASDAQ:MGTX opened at $8.56 on Wednesday. MeiraGTx has a 52 week low of $4.55 and a 52 week high of $9.50. The stock has a market capitalization of $688.65 million, a P/E ratio of -4.20 and a beta of 1.35. The firm has a fifty day simple moving average of $8.10 and a two-hundred day simple moving average of $7.31. The company has a quick ratio of 0.88, a current ratio of 0.88 and a debt-to-equity ratio of 26.29.

Insider Activity at MeiraGTx

In other MeiraGTx news, CEO Alexandria Forbes sold 47,500 shares of the business’s stock in a transaction that occurred on Tuesday, October 7th. The stock was sold at an average price of $8.39, for a total transaction of $398,525.00. Following the completion of the transaction, the chief executive officer owned 1,313,983 shares in the company, valued at $11,024,317.37. The trade was a 3.49% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Richard Giroux sold 24,000 shares of the business’s stock in a transaction that occurred on Tuesday, October 21st. The shares were sold at an average price of $8.87, for a total value of $212,880.00. Following the transaction, the chief financial officer owned 829,494 shares of the company’s stock, valued at $7,357,611.78. This trade represents a 2.81% decrease in their position. The disclosure for this sale is available in the SEC filing. 7.50% of the stock is owned by insiders.

Institutional Trading of MeiraGTx

A number of large investors have recently made changes to their positions in MGTX. BNP Paribas Financial Markets boosted its position in MeiraGTx by 43.8% in the 2nd quarter. BNP Paribas Financial Markets now owns 4,810 shares of the company’s stock valued at $31,000 after buying an additional 1,466 shares during the period. Tower Research Capital LLC TRC boosted its holdings in shares of MeiraGTx by 390.9% in the second quarter. Tower Research Capital LLC TRC now owns 8,797 shares of the company’s stock valued at $57,000 after purchasing an additional 7,005 shares during the period. Quantinno Capital Management LP purchased a new stake in shares of MeiraGTx in the second quarter valued at approximately $319,000. Brown Advisory Inc. purchased a new stake in shares of MeiraGTx in the 2nd quarter worth $326,000. Finally, Sender Co & Partners Inc. purchased a new stake in shares of MeiraGTx in the 2nd quarter worth $395,000. 67.48% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on MGTX shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of MeiraGTx in a research report on Wednesday, October 8th. Chardan Capital reiterated a “buy” rating and issued a $35.00 price target on shares of MeiraGTx in a research report on Friday, August 15th. Finally, Raymond James Financial assumed coverage on MeiraGTx in a report on Tuesday, October 21st. They issued a “strong-buy” rating and a $29.00 target price for the company. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $25.67.

About MeiraGTx

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia.